New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
04:55 EDTPFE, PFE, PFE, DNA, DNA, DNA, DRTX, DRTX, DRTX, ACRX, ACRX, ACRX, CEMP, CEMP, CEMP, CUR, CUR, CUR, MRNA, MRNA, MRNA, NVO, NVO, NVO, MRK, MRK, MRK, ABBV, ABBV, ABBV, AZN, AZN, AZN, AMGN, AMGN, AMGN, RHHBY, RHHBY, RHHBYEBD Group to hold a conference
BIO-Europe Spring 2014 is being held in Turin, Italy on March 10-12.
News For PFE;AMGN;AZN;ABBV;MRK;NVO;MRNA;CUR;CEMP;ACRX;DRTX;DNA;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 24, 2015
11:02 EDTPFEPfizer lung cancer treatment granted FDA orphan drug designation
Subscribe for More Information
09:07 EDTAZN, RHHBY, PFE, MRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
06:12 EDTABBVAbbVie announces new TURQUOISE-III study results
Subscribe for More Information
June 23, 2015
16:29 EDTCEMPOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
14:17 EDTPFEGlycoMimetics to receive $20M payment from Pfizer
Subscribe for More Information
14:01 EDTPFEPfizer announces enrollment of first patient in RESET study
Subscribe for More Information
09:53 EDTPFEPfizer management to meet with FBN Securities
Meeting to be held in New York on June 25 hosted by FBN Securities.
08:14 EDTCEMPCempra price target raised to $57 from $44 at Stifel
After meeting with Cempra's management, Stifel thinks the company has a number of near-term positive catalysts. The firm says that the stock's risk/reward appears to be positive heading into data on the company's solithromycin drug that is due to be released at the end of the year. Stifel keeps a Buy rating on the stock.
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
07:25 EDTPFE, AMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
08:52 EDTPFEPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
07:01 EDTPFEPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.
June 21, 2015
13:14 EDTMRKMerck shares could return 25%, Barron's says
Subscribe for More Information
June 19, 2015
16:02 EDTAMGNAmgen presents open-label extension data for Phase 2 study of migraine treatment
Subscribe for More Information
07:23 EDTAMGNTeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.
June 18, 2015
16:06 EDTAMGNAmgen says Phase 3 trial of Vectibix met primary endpoint
Subscribe for More Information
09:35 EDTPFEActive equity options trading on open
Subscribe for More Information
07:36 EDTABBV, AZNReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use